エドガーで原本を確認する
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15b-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2025
Commission File Number: 001-41359
Belite Bio, Inc
(Exact name of registrant as specified in its charter)
Not Applicable
(Translation of Registrant´s name into English)
12750 High Bluff Drive Suite 475,
San Diego, CA 92130
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
| Form 20-F x | Form 40-F ¨ |
All of the proposed resolutions as set out in Belite Bio, Inc’s Notice of Annual General Meeting of Shareholders dated March 18, 2025 were duly passed at its 2025 Annual General Meeting of Shareholders held on April 15, 2025. An announcement with respect to the foregoing is attached as exhibits to this Form 6-K and is incorporated by reference herein.
This Report on Form 6-K shall be deemed to be incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933, and shall be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
Exhibit 99.1 — Results of the 2025 Annual General Meeting of Shareholders
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Belite Bio, Inc | ||
| By: | /s/ Yu-Hsin Lin | |
| Name: | Yu-Hsin Lin | |
| Title: | Chief Executive Officer and Chairman | |
Date: April 15, 2025
Exhibit 99.1
Belite Bio Announces Results of 2025 General Meeting
SAN DIEGO, April 15, 2025 - Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announces the resolutions adopted at its 2025 general meeting of shareholders held in San Diego on April 15, 2025.
At the meeting, Belite’s shareholders approved (i) the re-election of Mr. Yu-Hsin Lin as a director of the Company; (ii) the re-election of Mr. Hao-Yuan Chuang as a director of the Company; (iii) the re-election of Ms. Wan-Shan Chen as a director of the Company; (iv) the re-election of Mr. John M. Longo as an independent director of the Company; (v) the re-election of Mr. Ita Lu as an independent director of the Company; (vi) the re-election of Mr. Gary C. Biddle as an independent director of the Company; (vii) the removal of Ms. Hung-Wei Chen as a director of the Company; and (viii) the election of Ms. Xiao-Hui Chen as a director of the Company.